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Abstract
Background: The AhR is a ligand-activated transcription factor that mediates immunosuppression induced by
environmental PAH and HAH. Recently, a critical role for the AhR in development of T cells involved in
autoimmunity (Th17 and Treg) has been demonstrated, supporting the hypothesis that the AhR plays a key role in
immune regulation both in the presence and absence of environmental ligands. Despite these results with T cells
systems, little is known of the role that the AhR plays in B cell development. We have demonstrated that B cell
activation with CD40 ligand, a stimulus that models adaptive immunity, induces AhR expression in primary human
B cells, suggesting that activation may increase human B cell sensitivity to AhR ligands and that the AhR may play
a role in B cell development.
Methods: To test these possibilities, we developed an in vitro system in which activated human B cells expressing
high AhR levels are induced to differentiate into plasma cells. Consequently, the effects of benzo [a]pyrene, a
prototypic environmental AhR ligand, on plasma cell differentiation could be investigated and this chemical could
be exploited essentially as drug probe to implicate the role of the AhR in plasma cell development.
Results: A previously unattainable level of B cell differentiation into plasma cells (up to 45% conversion) was
observed. Benzo [a]pyrene significantly suppressed that differentiation. g-Irradiation after an initial proliferation
phase induced by CD40 ligand and immediately prior to initiation of the differentiation phase blocked cell growth
but did not affect cell viability or plasma cell differentiation. B [a]P suppressed differentiation whether or not cell
growth was inhibited by g-irradiation.
Conclusions: 1) Extensive proliferation is not required during the differentiation phase per se for CD40L-activated
human B cells to undergo plasma cell differentiation, and 2) an environmental PAH blocks both proliferation and
differentiation of AhR expressing B cells. The results uncover a new mechanism by which environmentally
ubiquitous PAHs may negatively impact human B cell-mediated immunity.
Background
Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous
environmental pollutants generated by the incomplete
combustion of carbon sources. Numerous studies have
demonstrated that a variety of PAHs are carcinogenic
and immunosuppressive. Indeed, carcinogenic PAHs,
such as benzo [a]pyrene (B [a]P), suppress both humoral
(B cell-mediated) and cellular (T cell-mediated) immune
responses. Most of these adverse effects are mediated by
the aryl hydrocarbon receptor (AhR), a cytosolic recep-
tor/transcription factor [1]. In some cases, lymphocyte
immunotoxicity may be mediated indirectly through
accessory cells. For example, PAH-induced pre-B cell
apoptosis is mediated by AhR-expressing stromal cells
in the bone-marrow microenvironment [2]. Direct
effects of other PAHs on transformed B cells also have
been reported [3]. Similarly, halogenated hydrocarbons
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impair the ability of thymic stroma to support develop-
ing T cell growth and/or differentiation [4-12].
Many studies that evaluate the mechanisms by which
PAHs, or other related AhR ligands (e.g. halogenated
aromatic hydrocarbons/HAHs), mediate immunosup-
pression have been performed in animal models. These
studies reveal that AhR ligands suppress immunity by
their ability to compromise virtually every stage of lym-
phocyte development, activation, and effector function
studied. In this regard, PAHs and/or HAHs suppress
mature B and T cell development in primary lymphoid
organs [4-12] as well as inhibit antibody production,
alloantigen-specific mixed-lymphocyte reactions, T cell
cytokine production, effector and memory T cell devel-
opment, cytotoxic T cell responses, and host resistance
to infectious agents and transplantable tumors [7,13-19].
Perhaps most intriguing are recent studies demon-
strating that the AhR is intimately involved in the devel-
opment of T cell subsets, e.g., regulatory T cells (Treg)
and IL-17-secreting Th17 cells, and that activation of
the AhR in vivo enhances autoimmunity, presumably by
up-regulating Th17 development and/or down-regulat-
ing Treg development [20-24]. This environmental che-
mical alteration in development of T cell subsets helps
explain the outcomes of pioneering studies of Kerkvliet
et al in which AhR activation was shown to suppress T
cell-mediated tumor immunity or allograft rejection
[25,26]. These results support our working hypothesis
that the AhR plays a key role in immune regulation and
that environmental AhR ligands can significantly com-
promise immunity by altering AhR-dependent lympho-
cyte development and/or function.
Despite these exciting results with T cells systems, lit-
tle is known of the role that the AhR plays in B cell
development in general and in human cells in particu-
lar. For example, while now classic studies demon-
strated that low doses of TCDD (10-9 M) suppress
antibody secretion by immmortalized murine B cell
lines [27,28], little is known of the ability of AhR
ligands to affect human B cell differentiation into
plasma cells, a critical event in the ultimate production
of protective antibodies. The studies that have been per-
formed in this area relied primarily on transformed cell
lines or mixed lymphocyte populations with which it is
difficult to pinpoint the cell subset directly affected by a
given AhR ligand.
To begin to bridge this gap, we developed an in vitro
model to demonstrate that activation of primary human
B cells with CpG or CD40L, stimuli that mimic innate
or adaptive B cell responses respectively, dramatically
increases AhR expression [29]. These results suggest
that B cell stimulation following pathogen exposure may
increase B cell sensitivity to environmental AhR ligands
through AhR up-regulation. Since CD40L-stimulated, B
cells undergo rapid proliferation in germinal centers fol-
lowing antigenic stimulation and then differentiate into
plasma cells, it seemed plausible that AhR ligands could
interfere with the growth of what is presumed to be B
cells expressing high AhR levels ("AhRhigh“) and/or their
differentiation into plasma cells. The former possibility
was confirmed by the demonstration that B [a]P inhibits
proliferation of CD40L-activated primary human B cells
[29]. To test the latter possibility, we defined conditions
under which purified human B cells could be induced to
undergo differentiation in vitro and then evaluated the
effects of B [a]P, a prototypical environmental PAH and
AhR ligand, on that process. The results demonstrate
that, while proliferation may be required for B cells to
reach a state at which they are capable of differentiating
into plasma cells, ongoing B cell proliferation is not
required during the differentiation process itself.
Furthermore, results suggest that an environmental
PAH acts directly on AhRhigh human B cells to suppress
their differentiation into plasma cells, and that different
classes of AhR ligands differentially affect biologic
outcomes.
Methods
Chemicals
B [a]P (Sigma, St. Louis, MO) was dissolved in dimethyl-
sulfoxide (DMSO) (Sigma). Cells were dosed from a
1000× stock so that the final concentration was 0.1%.
Cell culture
CD40L-transfected L cells (American Type Tissue Cul-
ture Collection, VA) were maintained at 37°C in 10%
CO2 in RPMI supplemented with 10% FBS, 2 mM L-
glutamine, 5 μg/ml Plasmocin (Invivogen, San Diego,
CA) and hypoxanthine thymidine (HT). Unless other-
wise indicated, all culture reagents were obtained from
Cellgro (Mediatech, Herndon, VA).
B cell preparation
Peripheral blood mononuclear cells (PBMC) were pre-
pared from anonymous individual blood donors (New
York Biologics, Inc., New Jersey, NY) by centrifugation
of 50-100 ml whole blood through Ficoll (Amersham
Biosciences, Uppsala, Sweden) as previously described
[29]. PBMCs were depleted of T cells by sheep red
blood cell (ICN Biomedicals, Aurora, OH) rosetting and
a second centrifugation through Ficoll. PBMCs were
stained with FITC-labeled CD20-specific antibody (BD
PharMingen (Chicago, IL) and purified by fluorescence-
activated cell sorting (MoFlo, Dako Cytomation) based
on forward and side scatter parameters and CD20
expression. Approximately 107 B cells (>99% CD20+)
were recovered per donor from approximately 108
PBMCs.
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Plasma cell generation (two step cell culture)
In the first stage of plasma cell generation, purified B
cells were plated at approximately 3 × 106 cells/well in
6-well plates on irradiated CD40L-transfected L cells in
B cell media (Iscove’s medium; Invitrogen, Carlsbad,
CA) supplemented with 5% human AB serum (MP Bio-
medicals), 50 μg/ml transferrin (Invitrogen), 0.5%
human serum albumin (Aventis Behring, Kanakakee,
IL), 5 μg/ml insulin (Sigma), and 25 μg/ml Plasmocin
plus the following cytokines: rIL-2 (50 U/ml), rIL-4 (50
ng/ml), rIL-10 (50 ng/ml) and rIL-12 (2 ng/ml). After 4
days of culture (step 2), B cells were harvested, washed
and seeded in a single well (24 well plate) at 4 × 105/ml
media containing rIL-2 (50 U/ml), rIL-6 (25 ng/ml), rIL-
10 (50 ng/ml), rIL-12 (2 ng/ml) and rIFN-a (100 U/ml)
in the absence of CD40L-transfected L cells. All cyto-
kines were obtained from Research Diagnostics Inc.
(RDI, Flanders, NJ). The cell recovery after the second 4
day culture was over 2 × 106 cells/well, representing
approximately a 6-fold increase in cell numbers during
the second culture.
Cells were treated with vehicle (DMSO) or 10-6 M B
[a]P dissolved in DMSO on the first day of culture
and/or on day 4 at the start of the second culture step.
For all studies, cells were washed extensively after the
first culture and the same number of viable cells,
4 × 105, was added to each well in the second (differen-
tiation) culture. In studies evaluating the requirement
for cell proliferation during plasma cell differentiation,
activated B cells were g-irradiated (700 Rads) on day 4
prior to the initiation of the second culture. Where
indicated, 30 μM ZVAD-fmk (Biomol International,
Plymouth Meeting, PA) was added during the second
culture step to maximize cell viability. Approximately
4 × 105 cells/ml were recovered in vehicle-treated wells
following cell irradiation with or without ZVAD-fmk
support.
Surface phenotype and viability of cultured B and
plasma cells
Cells were harvested on day 8 of culture and viability
was determined by trypan blue and propidium iodide
exclusion by light microscopy and flow cytometry,
respectively. Phenotypic analyses of B and plasma cells
were performed using FITC-conjugated anti-CD20, PE-
conjugated anti-CD38 antibody (BD PharMingen (Chi-
cago, IL) or fluorochrome-labeled isotype controls. Non-
specific mAb binding was blocked by incubating cells
for 10 min in PBS containing 5% FBS, 1% sodium azide
and 0.01 mg/ml normal mouse IgG (Caltag Laboratories,
Burlingame, CA). Cells then were labeled with mAb or
isotype matched control antibodies according to the
manufacturer’s instructions. Following one wash, cells
were fixed in PBS containing 3.7% paraformaldehyde
and analyzed in a Becton Dickinson FACScan flow cyt-
ometer using CellQuest software (BD Biosciences).
Quadrants were set using dot plots obtained with iso-
type controls.
Giemsa stain
Following the second culture, sorted CD20lo/CD38hi
cells were resuspended in PBS (70,000 cells/100 μl) and
cytocentrifuged (Thermo Shandon, Thermo Electron
Corporation, Pittsburg, PA) for 5 minutes at 400 rpm
onto pre-cleaned Colorfrost/Plus microscope slides
(Fisher Scientific). Slides were immediately fixed with
90% ethanol for 1 minute and allowed to dry before
staining for 30 minutes with 1:4 Giemsa stain/deionized
water solution (Sigma). Excess stain was removed from
slides by dipping in water, followed by dipping in 0.01%
acetic acid. Slides were dehydrated by dipping into 95%
ethanol and 100% ethanol, placed into xylene and
mounted with Permount (Fisher Scientific) and a cover-
slip. Images were digitally captured using DIC optics
(Nikon).
Proliferation assays
CD40L-activated B cells were plated at a density of 105
cells/well into 96-well plates for 20 hours. [3H]-thymi-
dine (1 μCi/well) was added and plates were incubated
for an additional 18 hours. Cells were harvested onto fil-
ter strips using a cell harvester (Brandel, Gaithersbug,
MD) and radionucleotide incorporation was measured
using a liquid scintillation counter (Wallac, Turku, Fin-
land). For each donor, B cell treatments were performed
in triplicate. The means of the triplicate radioactivity
counts per minute (cpm) from each donor were used to
obtain an average for each indicated data point.
Apoptosis assay
Primary cultured B cells were harvested and washed
once with cold PBS containing 5% FBS and 0.01 M
sodium azide (Sigma). For propidium iodide (PI) stain-
ing, cells were resuspended in 0.15 ml hypotonic buffer
containing 50 μg/ml PI (Sigma), 0.1% sodium citrate
and 0.1% Triton X-100 and analyzed by flow cytometry
as we previously described [1,29-31]. Cells undergoing
DNA fragmentation (i.e. apoptosis) have a weaker PI
fluorescence than those in the typical G0/G1 stages of
cell cycle [31].
Statistical Analyses
The Student’s paired t-test and one-factor ANOVA were
used to analyze the data using Statview (SAS Institute,
Cary, NC). For ANOVA, the Dunnett’s or the Tukey/
Kramer multiple comparisons tests were used to com-
pare experimental and vehicle-treated groups or to com-
pare all possible combinations of groups respectively.
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Results
Generation of plasma cells using two-step cell cultures
In order to address whether environmental AhR ligands
affect the differentiation of human B cells into plasma
cells, it was necessary first to develop an in vitro differen-
tiation system in which significant numbers of human
plasma cells could be reliably generated from activated,
AhRhigh B cells. To this end, modifications were made to
previously published protocols in which activation of
human B cells was shown to significantly up-regulate
AhR expression [32,33]. In the first phase of the protocol,
CD20+ human B cells, purified from PBMC by fluores-
cence-activated cell sorting, were activated by growth on
monolayers of human CD40L-transfected L cells for 4
days in the presence of rIL-2, rIL-4, rIL-10 and rIL-12.
Robust B cell proliferation was observed during the
first culture period with B cell numbers increasing
approximately 8-fold [29]. Significant up-regulation of
AhR expression occurred within 24 hours of CD40L
activation and remained high for several weeks [1,29].
After this first culture, the cells expressed high levels of
CD20 and low levels of the plasma cell/activated lym-
phocyte marker CD38 (Figure 1A, center dot plot).
Activated CD20hi/CD38lo B cells then were cultured
for an additional 4 days with rIL-2, rIL-10, rIL-12, rIL-6,
and rIFN-a but without rIL-4 or CD40L-transfected
cells. Although stimulation through CD40 ceased after
the first culture of our system, B cell continued to divide
during a second culture period. In control cultures from
individual experiments using cells from five donors, the
number of cells harvested at the end of the eight day
culture period (2.6 × 106 ± 0.1 cells/well; Figure 2D,
first histogram) was approximately 6-fold higher than
the number plated on day four, demonstrating a signifi-
cant level of proliferation during the second culture.
(Note that the number of cells entering the second
culture was always adjusted to a constant number,
i.e., 4.0 × 105 cells/well). Following this second culture
CD40-B cells
(day 4)
PBMC
(day 0)
Differentiated PC
(day 8)
CD20
C 
D 
3 
8
Giemsa
C
D
38
A
B
Figure 1 Differentiation of peripheral human B cells into plasma cells. CD20hi B cells were purified by fluorescence-activated cell sorting
and activated for 4 days on CD40L-expressing cells in the presence of rIL-2, rIL-4, rIL-10, and rIL-12. Activated B cells then were adjusted to 4.0 ×
105 cells/ml and cultured for an additional 4 days without CD40L cells but with rIL-2, rIL-6, rIL-10, rIL-12 and rIFN-a. A) The phenotype of fresh
PBMCs prior to sorting, and of B lineage cells obtained after the first and second cultures was determined by flow cytometry following staining
with CD20- and CD38-specific or isotype control monoclonal antibodies. Quadrants were set using isotype control antibodies. CD20high/CD38low
starting B cells and CD20lo/CD38hi plasma cells are indicated by the octagons in the leftmost and rightmost dot plots respectively. B) CD20lo/
CD38hi cells generated after the second culture were sorted by flow cytometry, cytocentrifuged onto glass slides, and treated with Giemsa stain
to visualize plasma cell morphology.
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step (culture day 8), 31 ± 17% (mean ± SE; n = 4
donors) of the cells expressed the phenotypic character-
istics of plasma cells, i.e. low CD20 and high CD38
expression (Figure 1A, right dot plot).
Although many studies validate this phenotype as a
hallmark of human antibody secreting plasma cells
[32,33], CD20lo/CD38hi cells induced in our two step
culture were sorted by flow cytometry to >95% purity
and stained with Giemsa to visualize cell morphology
and to formally confirm their identity as plasma cells.
As expected, these cells displayed morphologic charac-
teristics of plasma cells, namely a basophilic cytoplasm,
an accentric nucleus, and a pale Golgi zone (Figure 1B).
It was concluded, therefore, that the 2-step culture was
suitable for analysis of plasma cell development in the
presence of environmental chemicals.
B [a]P suppresses production of plasma cells
To determine the effect of B [a]P exposure on the pro-
duction of plasma cells, B cells were treated with vehicle
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Figure 2 B [a]P suppresses plasma cell production. Purified CD20+ B cells from 4 donors were individually cultured in two steps as in Figure
1 to generate plasma cells. Cultures were treated with vehicle or 10-6 M B [a]P during the first (B [a]P/VEH), the second (VEH/B [a]P), or both (B
[a]P/B [a]P) culture periods. A) Dot plots of cells obtained from a representative donor stained with CD20- and CD38-specific or isotype control
antibodies are shown. Quadrants were set using isotype control antibodies. The percentages of CD20lo/CD38hi plasma cells are indicated in the
upper left quadrants. B) The percentages of CD20lo/CD38hi plasma cells obtained after the second culture period when cells were exposed to
vehicle or B [a]P during the first, second, or both cultures are presented as means + SE. C) The total number of CD20lo/CD38hi plasma cells
obtained after both cultures (day 8) are presented as means + SE. D) The total number of cells obtained after both cultures are presented as
mean + SE. An asterisk (*) indicates a significant decrease relative to vehicle-treated cells (p < 0.05; Dunnett’s).
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or 10-6 M B [a]P during the first and/or second culture
step and the number of CD20lo/CD38hi plasma cells was
assessed. Although individual experiments occasionally
suggested a decrease in the percentage of CD20lo/
CD38hi plasma cells after treatment with B [a]P during
both cultures (e.g., Figure 2A, lower right dot plot), no
significant differences were observed overall in the per-
centage of plasma cells generated in cultures exposed to
B [a]P during any point of the cultures (Figure 2B).
Treatment with B [a]P during either the first or the sec-
ond culture tended to decrease the absolute number of
plasma cells recovered, although statistical significance
(p < 0.05) was not reached unless B [a]P was present in
both cultures (Figure 2C). The apparent decrease in
plasma cell yield following B [a]P exposure coincided
with a significant decrease in the total number of cells
in cultures treated during the first, second, or both cul-
tures (Figure 2D). B [a]P did not induce significant
levels of overt death or apoptosis, as assayed by trypan
blue exclusion and propidium iodide staining and flow
cytometry, under any of the conditions shown in Figure
2 (~7% apoptotic in both vehicle and B [a]P-treated cul-
tures). These experiments indicate that B [a]P signifi-
cantly reduces the total number of B cells and
compromises the production of plasma cells in this
model. However, they do not distinguish between B [a]
P-mediated effects on B cell proliferation during the sec-
ond, differentiation culture, from proliferation-indepen-
dent effects on B cell differentiation into plasma cells.
B [a]P suppresses plasma cell differentiation during
conditions of minimal proliferation
It has been proposed that differentiation of B cells into
plasma cells requires cell proliferation, at least during an
initial stage of activation during which activated B cells
become differentiation-competent [34-39]. As noted
above, CD40L-activated B cells proliferate during both
the initial activation culture and the subsequent differ-
entiation culture. Previously, we demonstrated that B [a]
P inhibits proliferation of CD40L-activated B cells
[34-39]. Consequently, the reduced recovery of plasma
cells in B [a]P-treated cultures could reflect a reduction
in cell proliferation required to generate differentiation-
competent cells during the first or second culture and/
or inhibition of differentiation itself in the second cul-
ture. To develop a model in which the effects of B [a]P
on B cell proliferation could be dissociated from its
putative effects on differentiation, purified human B
cells were activated for the first four days with CD40
ligand with cytokines and then g-irradiated (700 Rads)
to block further cell proliferation.
As expected, little or no growth was observed in the
irradiated B cells, as indicated by the minimal level of
[3H]-thymidine incorporation during an 18 hour period
following irradiation (Figure 3A). When irradiated B
cells were re-cultured under conditions that induce
plasma cell differentiation, 41.8 ± 3.2% (mean ± SE, n =
4 donors) of the cells differentiated into CD20lo/CD38hi
plasma cells (e.g. Figure 3B). This level of plasma cell
differentiation was comparable to that seen in non-irra-
diated cultures (Figure 2). These results demonstrate
Figure 3 g-Irradiation inhibits cell growth but has no effect on
B cell differentiation into plasma cells. Purified CD20+ B cells
were activated for 4 days as described in Figure 1. Activated B cells
were then g-irradiated (700 Rads) and cultured without CD40L-
transfected cells but with IL-2, IL-6, IL-10, IL-12 and IFN-a. A) [3H]-
thymidine was added to cultures of irradiated and control cells at
21 hours and [3H]-thymidine incorporation assayed 18 hours later.
Data from 3 donors are presented as mean cpm ± SE. An asterisk
indicates a significant decrease in [3H]-thymidine incorporation as
compared with corresponding non-irradiated controls (p < 0.05;
paired t-test). B) Cells cultured as in “A” above were phenotyped for
CD20 and CD38 expression by flow cytometry 4 days after
irradiation and culture under plasma cell differentiation conditions.
Dot plots obtained with cells from a representative donor are
shown. The percentage of CD20lo/CD38hi plasma cells is indicated
in the upper left quadrant.
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that inhibition of cell division during the second stage
culture has no discernable effect on differentiation, a
result consistent with the hypothesis that, after an initial
proliferative phase, differentiation can occur in the
absence of continual cell proliferation [33,40-43].
Given these results, it was possible to determine the
putative effects of B [a]P exposure on plasma cell differ-
entiation during the second culture under conditions of
minimal cellular proliferation. Treatment of activated,
irradiated human B cells with B [a]P only during the dif-
ferentiation phase (i.e., the second culture) significantly
reduced the percentage (Figure 4A and 4B: VEH/B [a]P)
and the absolute number (not shown) of CD20lo/CD38hi
plasma cells recovered. These results strongly suggest
that B [a]P inhibits the process of plasma cell differen-
tiation independent of its ability to suppress prolifera-
tion of activated B cells.
Similarly, treatment with B [a]P in the first culture
step, during which extensive proliferation takes place,
resulted in a significant reduction in the number (not
shown) and percentage of plasma cells recovered (Figure
4A and 4B: B [a]P/VEH). B [a]P treatment during both
cultures (B [a]P/B [a]P) resulted in the greatest decrease
in the percentage of plasma cells recovered, a result
consistent with an additive effect of B [a]P on the gen-
eration/proliferation of differentiation-competent B cells
in the first culture and on their ability to differentiate
into plasma cells in the second culture.
Irradiated cells treated with vehicle or B [a]P appeared
as healthy as non-irradiated cells at the end of culture
as assessed by trypan blue and propidium iodide stain-
ing (~7% apoptotic). Nevertheless, it seemed formally
possible that the apparent block by B [a]P of B cell dif-
ferentiation could in part reflect preferential death of
short-lived plasma cells [36] upon B [a]P exposure. To
address this possibility, a separate series of experiments
was performed in which a relatively high dose (30 μM)
of a potent pan-caspase inhibitor, ZVAD-fmk [31], was
added to the second culture to minimize B/plasma cell
apoptosis. We have shown that >15 μM ZVAD-fmk or
other caspase inhibitor efficiently blocks PAH-induced
apoptosis of bone marrow B cell cells in vitro [31].
Apoptosis was measured by permeabilizing cells and
staining DNA with propidium iodide, as described pre-
viously [31]. A relatively small population of cells (4.6 +
0.89%) was undergoing apoptosis following vehicle treat-
ment (Table 1). No significant differences in the percen-
tage of apoptotic cells were observed when cells were
treated with B [a]P (Table 1). Nevertheless, B [a]P,
added either at the beginning of the first culture period
or during the differentiation stage, significantly
decreased the percentage of CD20lo/CD38hi plasma cells
recovered (Figure 5A, B). These results are equivalent to
those obtained with irradiated cells in the absence of
ZVAD-fmk (Figure 4). Therefore, it is concluded that
the decrease in plasma cell recovery seen after B [a]P
treatment of the second, differentiation culture results
primarily from a block in plasma cell differentiation and
not from inhibition of growth or from overt toxicity
manifest as preferential plasma cell death.
Discussion
The adverse effects of PAH exposure on B cell-depen-
dent, immune responses have been well documented
[44-46]. While many studies performed in animal mod-
els demonstrated reduced immunoglobulin levels follow-
ing in vivo or in vitro treatment with PAHs such as B
[a]P or DMBA, the exact cellular mechanisms, e.g., inhi-
bition of antigen presentation, reduction in T helper
activity, or inhibition of antibody secretion, was gener-
ally not investigated and indeed could not be evaluated
in the context of mixed lymphocyte populations. A sig-
nificant advance came with the demonstration that an
AhR ligand suppresses LPS-induced antibody secretion
in a transformed murine B cell line in vitro [47,48].
While these studies demonstrated a mechanism through
which an activated AhR could suppress immunoglobulin
gene transcription, they did not address the effect of
AhR ligands on the process of differentiation per se
from activated B cell to plasma cell. The present study
is the first to address specifically this issue and to
extend studies to nontransformed, highly enriched pri-
mary human cells.
In addition, the current studies were motivated by our
finding that human B cells, activated through CD40L as
a surrogate for antigen-stimulated CD40L+ T helper
cells, up-regulate AhR expression within 24 hours by
approximately 5-fold [29]. In addition to suggesting the
possibility that the AhR plays an important role in B
cell function, these results led us to investigate whether
activated B cells undergo normal levels of proliferation
and differentiation in the presence of AhR ligands.
Treatment of purified human B cells with B [a]P dur-
ing either the first or second stage of culture resulted in
a significant decrease in the total number of cells recov-
ered (Figure 2C and 2D). This result alone indicates that
suppression of humoral immunity may be mediated by
direct effects of PAHs on activated AhRhigh B cells. The
maximal decrease in the number of plasma cells
observed after B [a]P exposure during the entire culture
period suggests an additive effect resulting from B [a]P
inhibition of both B cell proliferation in the first culture
and differentiation in the second.
In order to distinguish between the effects of B [a]P on
B cell proliferation from additional effects on differentia-
tion, we developed a system in which plasma cell differ-
entiation could be studied under conditions of minimal
cell proliferation. To this end, cells were g-irradiated
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Figure 4 B [a]P suppresses plasma cell differentiation under conditions of minimal proliferation. Purified B cells were activated for 4 days
as described in Figure 1. B cells then were g-irradiated (700 Rads) and re-cultured for an additional 4 days under plasma cell differentiation
conditions. Cells were treated with vehicle or 10-6 M B [a]P during the first and/or second culture periods. A) Cells were phenotyped for CD20
and CD38 expression by flow cytometry. Dot plots obtained with cells from a representative donor (4 total) are shown. The percentages of
CD20lo/CD38hi plasma cells are indicated in the upper left quadrants. B) Data from cells obtained from four donors and treated as in “A” are
presented as mean percentage of CD20lo/CD38hi cells + SE. An asterisk (*) indicates a significant decrease relative to vehicle-treated cells
(p < 0.05; Dunnett’s).
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prior to the differentiation (second) culture. Prior to this
stage, activated B cells do not express any markers char-
acteristic of plasma cells. Radiation (700 R) significantly
reduced proliferation without inducing apoptosis, as
measured by propidium iodide staining or overt death as
measured by trypan blue exclusion. Notably, the greater
than 90% decrease in cell proliferation during the critical
stage of differentiation, i.e., the second culture, had no
effect on plasma cell differentiation. This important
result extends previous reports in which it was concluded
that extensive proliferation of B cells is required prior to
differentiation into plasma cells [34-36,39]. In fact, the
data presented herein indicate that, while CD40L+ T cell-
dependent proliferation of B cells prior to a differentia-
tion signal may be required to generate “differentiation-
competent” cells, little or no cell division is required dur-
ing the differentiation phase itself [40-43,49].
To evaluate the effects of B [a]P on differentiation per
se, B cells were irradiated at the beginning of the second
culture to inhibit proliferation and then exposed to vehi-
cle or B [a]P. B [a]P reduced the number (not shown)
and percentage (Figure 4) of CD20lo/CD38hi plasma cells
significantly, thereby demonstrating for the first time that
this prototypic PAH directly inhibits differentiation of B
cells into plasma cells. It also was interesting to note that
treatment of B cells during the first culture only, and
prior to irradiation and differentiation, also decreased the
percentage of plasma cells recovered despite the fact that
cells were washed extensively to remove B [a]P and that
cell numbers were adjusted to a standard level (4 × 105
cells/well) for the second culture. These results are con-
sistent with the hypothesis that, by suppressing cell divi-
sion, B [a]P exposure reduces the number of B cells that
are competent to undergo differentiation, thereby nega-
tively impacting the production of plasma cells.
While the mechanism underlying the block in B cell
differentiation into plasma cells is not known, several
possibilities exist. Pax5 is a transcription factor that pro-
motes transcription of B cell lineage genes while
repressing J-chain, IgH and XBP-1 genes, expression of
which is necessary for plasma cell differentiation [49].
Notably, the murine and human Pax5 promoters contain
three AhR response elements (AhREs), affording a direct
transcriptional mechanism through which the AhR
could up-regulate the expression of Pax5 and suppress
genes required for plasma cell differentiation. In support
of this possibility, at least one AhR ligand, TCDD, pre-
vents an LPS-mediated decrease in Pax5 expression and
suppresses antibody secretion in a transformed murine
B cell line, CH12.LX [50].
A second mechanism through which AhR activation
may alter the expression of genes required for plasma
cell differentiation is through the modulation of Pax5
transcriptional activity. The Pax5 DNA recognition
sequence (G/ANNCANTGNNGCGT/GG/AACC/GA/G)
contains a consensus AhR ‘core’ binding site (bold) [51].
In fact, AhR found in nuclear extracts prepared from
two human B cell lines recognizes a consensus Pax5
binding site in the CD19 promoter [52]. Therefore, it is
possible that B [a]P augments repression of genes
required for plasma cell differentiation, e.g. XBP-1, by
virtue of their expression of Pax5/AhR binding sites.
The ability of B [a]P to suppresses plasma cell differen-
tiation in the system described herein could reflect the
ability of B cells to metabolize B [a]P. In this vein, we have
shown that CYP1A1-dependent B [a]P metabolism into B
[a]P-7,8 dihydrodiol-9,10-epoxide is required for suppres-
sion of CD40L-activated B cell proliferation [1]. Further-
more, B [a]P can be metabolized by cellular peroxidases to
form B [a]P-quinones. These metabolites are converted
into reactive oxygen species that induce oxidative stress.
Cellular redox potential controls the DNA binding activity
of several transcription factors, including NF-B, AP-1,
and p53 [53-57]. In addition, oxidative stress in human B
cells induces expression of a multifunctional enzyme
known as APE/Ref-1 (or HAP-1)[58]. APE/Ref-1 modu-
lates the DNA binding activity of transcription factors
such as Pax5 by reducing cysteine residues [59-62]. While
oxidized Pax5 is unable to bind DNA, reduced Pax5 binds
DNA regulatory sites with high affinity [58,61,62]. Thus,
oxidative stress induced by B [a]P-quinones or B [a]P-
epoxides may activate APE/Ref-1, which in turn promotes
Pax5 transcriptional activity suppressing XBP-1 expression
and plasma cell differentiation.
Regardless of the mechanism(s) through which B [a]P
inhibits plasma cell differentiation, the data presented
here demonstrate a second level, in addition to inhibi-
tion of B cell growth [1], through which this prototypic,
environmental PAH is likely to suppress B cell
responses. Collectively, the data support the hypothesis
that up-regulation of AhR expression in activated
human B cells renders them particularly susceptible to
immunosuppressive PAHs.
Table 1 B [a]P does not induce apoptosis during
differentiation of irradiated B cells to plasma cells
Treatment % Apoptotic Cells
Vehicle/Vehicle 4.6 ± 0.9
Vehicle/B [a]P 6.5 ± 1.1
B [a]P/Vehicle 6.4 ± 0.8
Cells were activated with CD40L + rIL-2, rIL-4, rIL-10, and rIL-12 with vehicle or
10-6 M B [a]P for 4 days as described in Materials and Methods. Cells were
harvested, washed, irradiated (700 Rads) and re-plated at a concentration of
4 × 105/ml in media containing rIL-2, rIL-6, rIL-10, rIL-12, and rIFN-a in the
absence of CD40L-transfected L cells and in the presence of vehicle or B [a]P.
The percentage of cells undergoing apoptosis on day 8 of culture was
quantified by propidium iodide staining of permeabilized cells followed by
flow cytometric analyses. Data are derived from samples shown in Figure 4
and are presented as means ± SE of cells falling into the sub G0/G1 peak as
we previously described [30,31].
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Figure 5 Preferential plasma cell apoptosis does not account for a decrease in the percentage of plasma cells in B [a]P-treated
cultures. Purified B cells were activated for 4 days as described in Figure 1. B cells then were g-irradiated and re-cultured in the presence of the
pan-caspase inhibitor ZVAD-fmk (30 μM) for an additional 4 days. Cells were treated with vehicle or 10-6 M B [a]P during the first and/or second
culture periods. A) Cells were phenotyped for CD20 and CD38 expression by flow cytometry. Dot plots obtained with cells from a representative
donor (4 total) are shown. The percentages of CD20lo/CD38hi plasma cells are indicated in the upper left quadrants. B) The percentages of
plasma cells (4 donors) obtained 4 days after irradiation (day 8) and after treatment with vehicle or 10-6 M B [a]P in the presence or absence of
30 μM ZVAD-fmk are presented as means ± SE. An asterisk indicates a significant decrease in the percentage of plasma cells relative to control,
vehicle-treated cells (p < 0.05; Dunnett’s test).
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Conclusions
Using a novel human B cell differentiation system it was
possible to evaluate the ability of environmental AhR
ligands to directly suppress human B cell differentiation
into plasma cells in the absence of other lymphoid cell
populations. From these studies it is concluded that at
least some AhR ligands are capable of suppressing the
differentiation of activated human B cells into plasma
cells without inducing cell death. Inhibition of differen-
tiation with a prototypic PAH was seen even in the
absence of B cell proliferation or significant levels of cell
death, suggesting that a specific AhR-regulated signaling
pathway(s) is impacted by PAH exposure. Taken with
our previous studies showing up-regulation of AhR
expression and activity in activated human B cells [29],
these studies support the hypothesis that activated B
cells, which express high levels of the AhR, are particu-
larly susceptible to PAH exposure and that the AhR
may play an important role in differentiation from acti-
vated B cell to plasma cell. These results suggest a
mechanistic underpinning for epidemiological studies in
which exposure to environmental chemicals, including
metabolizable AhR ligands, results in reduced antibody
responses [63].
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